Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study

What Was Tested

Researchers studied Octreotide and Somatostatin in this clinical trial publication.

The aim of the study was to investigate the 5-yr impact of surgery and somatostatin analogs (SSA) on glucose metabolism in acromegaly.

Who Took Part

The study group was 100 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

The 100 patients (48 women, 52 men; median age, 49 yr) in the study were grouped as follows for treatment: SSA only (group A; n = 34); SSA followed by surgery (group B; n = 20); surgery only (group C; n = 30); and surgery followed by SSA (group D; n = 16).

How the Study Was Run

The researchers conducted an observational, prospective, comparative, nonrandomized study.

What Was Measured

Topics PubMed links to this paper include Acromegaly, Algorithms, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Longitudinal Studies and Octreotide.

What This Means in Plain Language

This is a clinical trial of Octreotide and Somatostatin in 100 patients.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.